Adair, Brian D.
Field, Conroy O.
Alonso, José L.
Xiong, Jian-Ping
Deng, Shi-Xian
Ahn, Hyun Sook
Mashin, Eivgeni
Clish, Clary B. http://orcid.org/0000-0001-8259-9245
van Agthoven, Johannes
Yeager, Mark
Guo, Youzhong http://orcid.org/0000-0001-7177-9603
Tess, David A.
Landry, Donald W.
Poncz, Mortimer
Arnaout, M. Amin http://orcid.org/0000-0002-8270-0371
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL141366)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK088327)
Article History
Received: 19 December 2023
Accepted: 21 September 2024
First Online: 4 October 2024
Competing interests
: M.A.A. and D.W.L. are co-founders of a 2021 startup aimed at generating and testing novel integrin antagonists. The other authors declare no competing interests.